(Q41509268)

1 October 2017

1 reference

title

Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease (English)

1 reference

1 October 2017

1 reference

1 reference

4

M M Mouradian

1 reference

1 October 2017

Blanchet PJ

1

1 reference

1 October 2017

Papa SM

series ordinal

2

1 reference

1 October 2017

Metman LV

series ordinal

3

1 reference

1 October 2017

Chase TN

series ordinal

5

1 reference

1 October 2017

1 July 1997

1 reference

Neuroscience & Biobehavioral Reviews

1 October 2017

1 reference

1 October 2017

21

1 reference

1 October 2017

447-453

1 reference

1 October 2017

4

1 reference

The functional anatomy of basal ganglia disorders

1 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Excitatory amino acid binding sites in the basal ganglia of the rat: A quantitative autoradiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

The distribution of excitatory amino acid receptors in the normal human midbrain and basal ganglia with implications for Parkinson's disease: a quantitative autoradiographic study using [3H]MK-801, [3H]glycine, [3H]CNQX and [3H]kainate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Acute pharmacologic blockade of dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Does levodopa aggravate Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Dextromethorphan and parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Antitussive agents as N-methylaspartate antagonists: further studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

NMDA receptor blockade reverses motor response alterations induced by levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Combined treatment of parkinsonism with L-dopa and amantadine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Antiparkinsonian activity of a single oral dose of PHNO

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Apomorphine-induced changes in striatal and pallidal neuronal activity are modified by NMDA and muscarinic receptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

1 reference

7 January 2021

Chronic administration of NMDA antagonists induces D2 receptor synthesis in rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

L-[3H]Glutamate binds to kainate-, NMDA- and AMPA-sensitive binding sites: an autoradiographic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Pathogenesis of dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

D2 dopamine receptor messenger RNA is altered to a greater extent by blockade of glutamate receptors than by blockade of dopamine receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Young onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Motor response to apomorphine and levodopa in asymmetric Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Facilitation of dopamine D1 receptor- but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy- piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

The competitive NMDA antagonist CGP40.116 enhances L-dopa response in MPTP-treated marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

Lamotrigine-antiparkinsonian activity by blockade of glutamate release?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900038-3

7 January 2021

10.1016/S0149-7634(96)00038-3

Identifiers

DOI

1 reference

1 October 2017

1 reference